Sponsor:
Novoic Limited
Code:
NCT04937959
Conditions
Alzheimer Disease
Alzheimer's Disease (Incl Subtypes)
Preclinical Alzheimer's Disease
Prodromal Alzheimer's Disease
Mild Cognitive Impairment
Eligibility Criteria
Sex: All
Age: 50 - 70+
Healthy Volunteers: Accepted
Brief summary:
Conditions
Alzheimer Disease
Alzheimer's Disease (Incl Subtypes)
Preclinical Alzheimer's Disease
Prodromal Alzheimer's Disease
Mild Cognitive Impairment
Study ID
NCT04937959
Start date
Jan 22, 2021
Status verified date
Jun, 2021
Completion date
Aug 30, 2022
Anticipated
Primary completion date
Aug 30, 2022
Anticipated
Eligibility Criteria
Sex: All
Age: 50 - 70+
Healthy Volunteers: Accepted
Enrollment
40 participants
Anticipated
Arms
Arm 1: MCI amyloid positive
Arm 2: MCI amyloid negative
Arm 3: CN amyloid positive
Arm 4: CN amyloid negative
Primary outcome measure
Central contacts
Locations
Syrentis Clinical Research
Recruiting
Santa Ana, California, United States, 92705
Contacts
Sponsor
Novoic Limited
Last update posted
Apr 7, 2022
Last verified
Jun, 2021
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Novoic Limited on 2022-04-07.